

Remarks:

Reconsideration of the application, as amended herein, is respectfully requested.

Applicant would like to thank the Examiner and her Supervisor Joseph Thomas for the courtesy and helpfulness shown to Applicant's representatives during a telephonic interview of August 17, 2005. It is believed that the amendments made to the current application are being made in accordance with those discussions. Prior to that telephonic interview, Applicant's representative provided the Office with a proposed amendment to claim 85. Applicant notes herein that the proposed amendment was not considered, nor was it entered in the present case, as it allegedly raised issues requiring a new search. As such, the amendments to claim 85 made herein are made with reference to claim 85, as it stood after Applicant's response of March 30, 2005.

Claims 71 - 73, 75 and 85 are presently pending in the application. Claims 71 and 85 have been amended.

In item 4 of the above-reference Office Action, an Examiner's amendment was proposed to change the phrase "may be" to "is" in claim 1. Claim 71 has been amended herein to address the proposed Examiner's amendment in item 4 of the Office Action and to replace the phrase "to enable" in item c) of the claim,

with the word "for", as was requested during the telephonic interview.

Applicant gratefully acknowledges that, in item 5 of the Office Action, claims 71 - 73 and 75, including the Applicant's particularly claimed "drug formulary information", were allowed.

In item 7 of the Office Action, claim 85 was rejected under 35 U.S.C. § 103(a) as allegedly being obvious over U. S. Patent No. 5,072,383 to Brimm et al. However, in the telephonic interview of August 17, 2005, it was indicated that, if claim 85 were amended to include the particularly claimed "drug formulary information" limitation of claim 71, that claim 85 would be in condition for allowance. As such, claim 85 has been amended to recite, among other limitations, the limitation of paragraph c) of claim 71, including the particularly claimed "drug formulary information". As such, it is believed that claim 85 is in condition for immediate allowance, and such action is respectfully requested.

It is accordingly believed that none of the references, whether taken alone or in any combination, teach or suggest the features of claims 71 and 85. Claims 71 and 85 are, therefore, believed to be patentable over the art. The

dependent claims are believed to be patentable as well because they all are ultimately dependent on claim 71.


In view of the foregoing, reconsideration and allowance of claims 71 - 73, 75 and 85 are solicited.

In the event the Examiner should still find any of the claims to be unpatentable, counsel would appreciate receiving a telephone call so that, if possible, patentable language can be worked out. In the alternative, the entry of the amendment is requested, as it is believed to place the application in better condition for appeal, without requiring extension of the field of search.

If an extension of time for this paper is required, petition for extension is herewith made.

Please charge any fees that might be due with respect to Sections 1.16 and 1.17 to the Deposit Account of Robert M. Schwartz, P.A., No. 19-0734.

Respectfully submitted,



For Applicant

Robert M. Schwartz
Reg. No. 29,854

KPS:cgm

August 19, 2005

Robert M. Schwartz, P.A.
Post Office Box 221470
Hollywood, FL 33022
Tel: (954) 924-0707
Fax: (954) 924-0717